+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuropathic Pain Drug Market by Product Type (Anticonvulsants, Antidepressants, Opioids), Route Of Administration (Intravenous, Oral, Topical), Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Neuropathic Pain Drug Market by Product Type (Anticonvulsants, Antidepressants, Opioids), Route Of Administration (Intravenous, Oral, Topical), Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Neuropathic Pain Drug Market by Product Type (Anticonvulsants, Antidepressants, Opioids), Route Of Administration (Intravenous, Oral, Topical), Indication, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968619
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuropathic pain drug market is at a pivotal juncture, shaped by a convergence of scientific progress, regulatory evolution, and changing healthcare priorities. Today’s senior decision-makers face an increasingly complex environment where strategic agility and data-driven insights are critical for gaining commercial advantage and meeting rising patient demands.

Market Snapshot: Neuropathic Pain Drug Market Growth

The Neuropathic Pain Drug Market grew from USD 12.90 billion in 2024 to USD 14.22 billion in 2025. It is expected to continue growing at a CAGR of 10.14%, reaching USD 23.04 billion by 2030. This forward trajectory is fueled by innovation in molecular biology, targeted therapies, and increasing real-world demand for effective pain management solutions.

Scope & Segmentation

This report delivers a multidimensional analysis of the neuropathic pain therapeutics landscape, focusing on products, administration modes, patient indications, distribution channels, and regional opportunities. The study also highlights recent technological advances transforming drug development and supply chain strategies in a competitive, regulatory-driven environment.

  • Product Types: Anticonvulsants (e.g., carbamazepine, gabapentin, lamotrigine, pregabalin), Antidepressants (SNRIs: duloxetine, venlafaxine; TCAs: amitriptyline, nortriptyline), Opioids (tapentadol, tramadol), Topical Agents (capsaicin, diclofenac gel, lidocaine patch)
  • Routes of Administration: Intravenous, Oral, Topical, Transdermal
  • Indications: Chemotherapy-induced neuropathy, Diabetic neuropathy, HIV-associated neuropathy, Post-herpetic neuralgia
  • Distribution Channels: Hospitals pharmacy, Retail pharmacies, Specialty clinics
  • Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (such as United Kingdom, Germany, France, Russia, UAE, South Africa); Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, and others)
  • Key Companies Profiled: Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Eli Lilly and Company, Grünenthal GmbH, Endo International plc, Bausch Health Companies Inc., Hikma Pharmaceuticals PLC, AcelRx Therapeutics, Inc.
  • Emerging Technologies: Digital therapeutics, high-throughput screening, biomarker discovery, gene therapies, neuromodulation devices, and real-world evidence platforms

Key Takeaways for Senior Leaders

  • Targeted pain therapeutics benefit from advances in molecular targeting, resulting in emerging drug classes that address diverse patient needs and mechanistic pathways.
  • Strategic collaborations between large pharmaceutical firms and nimble biotechs are accelerating clinical innovation and risk-sharing in drug development.
  • Digital health and patient engagement platforms are enhancing adherence, providing real-time monitoring, and complementing traditional drug modalities.
  • Market access requires robust evidence packages with both clinical efficacy and health economics outcomes to meet payer expectations and facilitate reimbursement.
  • Corporate diversification into device integration, biomarker-driven trial designs, and end-to-end patient support solutions is redefining the competitive landscape.

Tariff Impact: United States Policy Implications

Revised United States tariff policies have introduced new pressures on input costs for imported raw materials and APIs, prompting industry leaders to reassess supplier relationships and contract terms. Organizations are responding with onshore manufacturing, diversification of regional supply partnerships, and flexible manufacturing platforms to bolster resilience and cost efficiency. Legal and compliance teams are now increasingly involved in ensuring transfer pricing aligns with global trade requirements, helping preserve both margins and patient access despite regulatory adjustments.

Methodology & Data Sources

This report relies on a rigorous mixed-method approach, blending interviews with clinical experts, decision-makers, and procurement specialists for qualitative insights. Quantitative validation is achieved through targeted stakeholder surveys. Secondary research includes detailed analysis of academic literature, regulatory submissions, company releases, and industry events. All findings are cross-validated using triangulation to ensure data robustness and reliability in actionable intelligence.

Why This Report Matters

  • Enables informed, strategic portfolio planning and investment prioritization in high-growth therapeutic areas.
  • Equips executives with actionable insights to respond to evolving market access requirements, regulatory challenges, and emerging technology trends.
  • Supports operational leaders in mitigating supply chain risks and optimizing launch strategies in diverse regional markets.

Conclusion

The neuropathic pain drug market invites decisive action from leaders ready to leverage innovation, resilient sourcing, and evidence-based strategies. This report provides the clarity required to navigate ongoing transformation and secure lasting competitive advantage.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of precision medicine and genetic profiling in neuropathic pain treatment options
5.2. Emergence of novel sodium channel blockers targeting Nav1.7 for postherpetic neuralgia management
5.3. Adoption of combination therapy protocols incorporating cannabinoids and gabapentinoids in peripheral neuropathy
5.4. Expansion of digital health monitoring tools for real-time assessment of neuropathic pain symptoms
5.5. Regulatory incentives driving development of orphan neuropathic pain indications in diabetic neuropathy
5.6. Pioneering use of gene therapy approaches to modulate pain signaling pathways in neuropathic patients
5.7. Impact of real-world evidence studies on formulary decisions for emerging neuropathic pain treatments
5.8. Growing focus on patient-centric outcome measures and quality-of-life endpoints in clinical trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neuropathic Pain Drug Market, by Product Type
8.1. Introduction
8.2. Anticonvulsants
8.2.1. Carbamazepine
8.2.2. Gabapentin
8.2.3. Lamotrigine
8.2.4. Pregabalin
8.3. Antidepressants
8.3.1. SNRIs
8.3.1.1. Duloxetine
8.3.1.2. Venlafaxine
8.3.2. TCAs
8.3.2.1. Amitriptyline
8.3.2.2. Nortriptyline
8.4. Opioids
8.4.1. Tapentadol
8.4.2. Tramadol
8.5. Topical Agents
8.5.1. Capsaicin
8.5.2. Diclofenac Gel
8.5.3. Lidocaine Patch
9. Neuropathic Pain Drug Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Topical
9.5. Transdermal
10. Neuropathic Pain Drug Market, by Indication
10.1. Introduction
10.2. Chemotherapy-Induced Neuropathy
10.3. Diabetic Neuropathy
10.4. HIV-Associated Neuropathy
10.5. Post-Herpetic Neuralgia
11. Neuropathic Pain Drug Market, by Distribution Channel
11.1. Introduction
11.2. Hospitals Pharmacy
11.3. Retail Pharmacies
11.4. Specialty Clinics
12. Americas Neuropathic Pain Drug Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Neuropathic Pain Drug Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Neuropathic Pain Drug Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.3. Mylan N.V.
15.3.4. Novartis AG
15.3.5. Eli Lilly and Company
15.3.6. Grünenthal GmbH
15.3.7. Endo International plc
15.3.8. Bausch Health Companies Inc.
15.3.9. Hikma Pharmaceuticals PLC
15.3.10. AcelRx Therapeutics, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. NEUROPATHIC PAIN DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. NEUROPATHIC PAIN DRUG MARKET: RESEARCHAI
FIGURE 24. NEUROPATHIC PAIN DRUG MARKET: RESEARCHSTATISTICS
FIGURE 25. NEUROPATHIC PAIN DRUG MARKET: RESEARCHCONTACTS
FIGURE 26. NEUROPATHIC PAIN DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 133. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 136. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 137. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 138. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 139. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 140. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 141. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 142. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 143. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 144. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 145. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 146. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 147. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 158. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 159. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 256. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 257. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 258. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 259. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 260. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 261. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 262. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 263. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 264. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 265. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 268. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 269. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 278. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 279. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 280. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 281. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 282. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 283. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 284. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 285. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 286. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 287. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 288. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 289. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 307. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 308. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 309. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 316. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 317. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 318. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 319. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 320. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 321. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 322. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 323. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 324. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 325. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 326. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 327. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
TABLE 328. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2030 (USD MILLION)
TABLE 329. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-20

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Novartis AG
  • Eli Lilly and Company
  • Grünenthal GmbH
  • Endo International plc
  • Bausch Health Companies Inc.
  • Hikma Pharmaceuticals PLC
  • AcelRx Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 14.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 23.04 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Diabetic Neuropathic Pain Market Report and Forecast 2025-2034 - Product Image

Diabetic Neuropathic Pain Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Neuropathic Pain - Global Strategic Business Report - Product Image

Neuropathic Pain - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Pain Management Therapeutics Market by Drug Class (Adjuvant Analgesics, Local Anesthetics, Neuropathic Pain Agents), Route Of Administration (Oral, Parenteral, Topical), Indication, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Pain Management Therapeutics Market by Drug Class (Adjuvant Analgesics, Local Anesthetics, Neuropathic Pain Agents), Route Of Administration (Oral, Parenteral, Topical), Indication, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Peripheral Neuropathic Pain-Pipeline Insight, 2025 - Product Image

Peripheral Neuropathic Pain-Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Neuropathic Pain Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Neuropathic Pain Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Neuropathic Pain Drug Market

The Neuropathic Pain Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neuropathic pain drugs are used to treat chronic pain caused by nerve damage, such as diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. These drugs are typically divided into two categories: anticonvulsants and antidepressants. Anticonvulsants are used to reduce the intensity of nerve pain, while antidepressants are used to reduce the frequency of nerve pain. Commonly prescribed neuropathic pain drugs include pregabalin, gabapentin, duloxetine, and amitriptyline. Some companies in the Neuropathic Pain Drug market include Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.